Ignat Patricia, Todor Nicolae, Ignat Radu-Mihai, Șuteu Ofelia
Faculty of Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Prof. Dr. I. Chiricuță Oncology Institute, 400015 Cluj-Napoca, Romania.
Curr Oncol. 2021 Oct 1;28(5):3876-3890. doi: 10.3390/curroncol28050331.
Treatment indication for bone metastases is influenced by patient prognosis. Single-fraction radiotherapy (SFRT) was proven equally effective as multiple fractionation regimens (MFRT) but continues to be underused.
Primary objectives: (a) to identify prognostic factors for overall survival and (b) to analyze treatment patterns of palliative radiotherapy (proportion of SFRT indication and predictive factors of radiotherapy regimen) for bone metastases.
582 patients with bone metastases who underwent conventional radiotherapy between January 1st 2014-31 December 2017 were analyzed. The Cox proportional hazard model was used to identify predictors of overall survival. For the treatment pattern analysis, 677 radiotherapy courses were evaluated. The logistic regression model was used to identify potential predictors of radiotherapy regimen.
The 3-year overall survival was 15%. Prognostic factors associated with poor overall survival were multiple bone metastases [hazard ratio (HR = 5.4)], poor performance status (HR = 1.5) and brain metastases (HR = 1.37). SFRT prescription increased from 41% in 2017 to 51% in 2017. Predictors of SFRT prescription were a poor performance status [odds ratio (OR = 0.55)], lung (OR = 0.49) and urologic primaries (OR = 0.33) and the half-body lower site of irradiation (OR = 0.59). Spinal metastases were more likely to receive MFRT (OR = 2.09).
Based on the prognostic factors we identified, a selection protocol for patients candidates for palliative radiotherapy to bone metastases could be established, in order to further increase SFRT prescription in our institution.
骨转移瘤的治疗指征受患者预后影响。单次分割放疗(SFRT)已被证明与多次分割放疗方案(MFRT)同样有效,但使用率仍然较低。
主要目标:(a)确定总生存的预后因素;(b)分析骨转移瘤姑息性放疗的治疗模式(SFRT指征比例及放疗方案的预测因素)。
分析了2014年1月1日至2017年12月31日期间接受传统放疗的582例骨转移瘤患者。采用Cox比例风险模型确定总生存的预测因素。对于治疗模式分析,评估了677个放疗疗程。采用逻辑回归模型确定放疗方案的潜在预测因素。
3年总生存率为15%。与总生存较差相关的预后因素为多发骨转移[风险比(HR = 5.4)]、体能状态差(HR = 1.5)和脑转移(HR = 1.37)。SFRT处方比例从2014年的41%增加到2017年的51%。SFRT处方的预测因素为体能状态差[比值比(OR = 0.55)]、肺癌(OR = 0.49)和泌尿系统原发肿瘤(OR = 0.33)以及下半身半身照射部位(OR = 0.59)。脊柱转移瘤更有可能接受MFRT(OR = 2.09)。
基于我们确定的预后因素,可以建立骨转移瘤姑息性放疗候选患者的选择方案,以进一步提高我院SFRT的处方比例。